By the time it’s registered, the vendor’s been picked.

It's a dedicated product built on the Salesmotion platform for life-sciences business development teams - CROs, bioanalytical labs, CDMOs, and service providers selling into biotech and pharma sponsors. It consolidates the pharma-news, contact, and clinical-trial tools BD teams juggle today into a single AI-native system: a global database of every sponsor, continuously discovered and classified, combined with deep business context and AI outreach.

Legacy pharma-news tools rely on manual verification, ship with rigid predefined filters, cap downloads on lower tiers, and stop at news. Salesmotion is AI-native - it discovers and classifies sponsors every day, gives you fully customizable filtering across therapeutic area, modality, pipeline phase, company size, and geography, and goes beyond news into financials, contact enrichment, and AI-drafted outreach in one platform.

General contact databases sell verified emails with no clinical or pipeline context, usually on premium annual contracts. Salesmotion delivers sponsor-grade contacts enriched with the trial pipeline, funding, and modality intelligence that life-sciences BD teams actually sell on - at a fraction of legacy contact-database pricing, with flexible monthly terms.

Yes, from the first public record a company leaves. Salesmotion continuously scans trial registries, regulatory and securities filings, grant awards, funding events, and corporate disclosures, which surfaces newly formed biotechs well before a trial registration, often at first financing, first grant, or the first regulatory and CMC hires that signal clinical intent.

Yes - accurate modality classification is a core design goal. Instead of keyword matching that tags an antibody company as small-molecule because of a single partnership mention, Salesmotion classifies sponsors by their actual pipeline, so a 'large molecule' or 'cell and gene therapy' filter returns the right companies without hours of manual cleanup.

Salesmotion detects events and gives you lead time, rather than forecasting a specific future date. The practical value is sequencing: regulatory and CMC hiring, financing, and phase transitions typically appear months before a sponsor formally goes to market for partners, so you can engage during the window when a decision is still being shaped. Anyone claiming to predict the month an RFP will issue is overstating what public data supports.

Contacts are surfaced by function rather than by seniority alone, so you can target clinical operations, CMC, analytical development, and regulatory affairs rather than defaulting to whoever ranks highest. This matters because the technical evaluator who writes the scope is usually two levels below the executive who approves it. Test it on your own target accounts during an evaluation.

Yes. Company profiles, signals (including clinical-trial fields) and contacts are available through the Salesmotion REST API and MCP server, and account intelligence syncs into Salesforce and HubSpot - so the same intelligence your reps use in the UI can power your own workflows, scoring models, and data warehouse.

First-in-human starts, Phase 1 through Phase 4 transitions, and trial completions - with particular emphasis on Phase 2 kickoffs and Phase 2 → Phase 3 transitions, the points where sponsors most often evaluate new partners. Funding rounds, leadership changes, and hiring surges fire as signals alongside the pipeline events.

The Life Sciences bundle is $200 a month for 200 tracked accounts and around five seats. The Life Sciences package is $500 a month for 500 accounts and up to 20 users. Extra accounts are $1 each per month in blocks of 100. A single seat is $85 a month for 100 accounts, though it does not include sponsor discovery. All monthly, with no annual lock-in.